Client news

A&O Shearman advises Boston Scientific Corporation on its USD15 billion proposed acquisition of Penumbra, Inc.

A&O Shearman advises Boston Scientific Corporation on its USD15 billion proposed acquisition of Penumbra, Inc.
Published Date
Jan 15 2026
Related people
Image of Derrick Lott
Derrick LottPartner, New York
Image of Clare O’Brien
Clare O’BrienPartner, New York
Image of Nwadi Oko
Nwadi OkoAssociate, New York
Jake ShaughnessyAssociate, New York
Musa Ya-SinAssociate, New York
Image of Melisa Brower
Melisa BrowerPartner, New York
Image of John Cannon
John CannonPartner, New York
Image of Janice Perri
Janice PerriAssociate, New York
Image of Stephen Ponticiello
Stephen PonticielloAssociate, New York
Image of JB Betker
JB BetkerPartner, New York
Image of Will Jackson
Will JacksonAssociate, New York
Image of Larry Crouch
Larry CrouchPartner, New York
Image of Anna Armao
Anna ArmaoAssociate, New York
A&O Shearman is advising Boston Scientific Corporation on its proposed acquisition of Penumbra, Inc., announced earlier today.   

The acquisition is projected to expand Boston Scientific’s cardiovascular portfolio and provide scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies. Penumbra’s comprehensive portfolio includes differentiated devices to treat complex conditions.

"We are proud to work alongside Boston Scientific on such a significant transaction."

Boston Scientific is a global medical technology company that develops devices and therapies used by physicians to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. With more than 45 years in the sector, the company focuses on advancing science to meet unmet patient needs and improve healthcare value.

Penumbra offers innovative mechanical thrombectomy products for peripheral vascular procedures. Its neurovascular offerings include solutions for access, stroke revascularization, and neuro embolization, supported by ongoing innovation and clinical evidence to broaden patient access.

“This acquisition supports Boston Scientific’s strategy to expand novel vascular and neurovascular technologies and participate in fast growing segments.”

The A&O Shearman team was led by New York-based M&A partners Derrick Lott and Clare O’Brien, with key support from associates Nwadi Oko, Jake Shaughnessy, and Musa Ya-Sin; partners Melisa Brower and John Cannon and associates Janice Perri and Stephen Ponticiello on employment and compensation matters; partner JB Betker and associate Will Jackson on IP matters; and partner Larry Crouch and associate Anna Armao on tax matters.

Related capabilities